Clean Science & Technology Ltd. · NSE:CLEAN
Clean Science & Technology — Q3 FY2026 Earnings Presentation
22 slides from Clean Science & Technology's earnings presentation, Jan 31, 2026
Slide 1: Stock exchange covering letter for investor presentation
31.01.2026 To, BSE Limited National Stock Exchange of India Limited Phiroze JeeJeebhoy Towers, Exchange Plaza, Plot no. C/1, Dalal Street, G Block, Bandra-Kurla Complex Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543318 Trading Symbol: CLEAN Subject: Investor Presentation. Dear S
Slide 2: Clean Science and Technology Ltd. Investor Presentation Q3 FY2026
Clean Science and Technology Ltd. Investor Presentation Q3 FY 2026 I JANUARY 2026
Slide 3: Safe Harbour
SAFE HARBOUR This investor presentation has been prepared by Clean Science and Technology Limited (“CSTL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered o
Slide 4: Q3 FY2026 & 9M FY2026 Business Update
Q3 FY 2026 & 9M FY2026 Business Update
Slide 5: Q3 FY2026 Update
Q3 FY2026 UPDATE EIBTDA margins resilient in challenging market conditions Revenue in INR Crore 225 217 228 232 245 220 212 185 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 44.4% 45.5% 42.1% 44.8% 43.8% 46.4% 44.3% 40.3% 34.7% 36.6% 35.7% 37.3% 36.1% 34.4% 34.1% 32.5% 8.7% 9.6% 9.
Slide 6: Q3 FY2026 P&L Overview
Q3 FY2026 P&L OVERVIEW Progressive growth in HALS business continues; commercialization of Hydroquinone and Catechol capacity to further accelerate sales growth P&L (INR Crore) STANDALONE CONSOLIDATED Particular Q3 FY2026 Q2 FY2026 Q-o-Q (%) Q3 FY2025 Y-o-Y (%) Q3 FY2026 Q2 FY2026 Q-o-Q (%) Q3 FY202
Slide 7: 9M FY2026 P&L Overview
9M FY2026 P&L OVERVIEW Steady revenues on account of increased contribution from new launches P&L (INR Crore) STANDALONE CONSOLIDATED Particular 9M FY2026 9M FY2025 Y-o-Y (%) 9M FY2026 9M FY2025 Y-o-Y (%) Sale of products 602 668 (10)% 696 694 - Other operating income 16 9 11 9 Total Revenue 618 677
Slide 8: Revenue Profile – 9M FY2026
REVENUE PROFILE –9M FY 2026 Performance segment share increased led by higher sales of HALS series REVENUE MIX BY SEGMENT REVENUE MIX BY GEOGRAPHY 7% 12% 9% 10% 17% 37% 18% 20% 38% 21% 9M FY’26 9M FY’25 9M FY’25 9M FY’26 76% 70% 14% 14% 18% 19% Performance Pharma & Agro FMCG China India Europe Ameri
Slide 9: Corporate presentation
Corporate presentation
Slide 10: Clean Science and Technology at a Glance
CLEAN SCIENCE AND TECHNOLOGY AT A GLANCE A brief Introduction about the Company ➢ One of the fastest growing and among the most profitable fine and specialty chemical companies globally. Among the largest manufacturers of certain specialty chemicals developed in-house. ➢ Among the few global organiz
Slide 11: Company Evolution
COMPANY EVOLUTION Continuous R&D and Innovation has led to new product launches on a consistent basis YEAR 2009 2011 2014 2018 2020 2021 2022 2023 2024 2025 REVENUES (INR Crore) 1 19 120 241 419 512 685 936 789 967 ➢ Commercialized largest plant for Genesis: HALS from India 2025 ➢ Technocrat Promote
Slide 12: Diversified Product Profile Serving Critical End-User Industries
DIVERSIFIED PRODUCT PROFILE SERVING CRITICAL END-USER INDUSTRIES Largest capacity in the world for our flagship products PERFORMANCE PHARMA AND AGRO FMCG CHEMICALS INTERMEDIATES CHEMICALS MEHQ (Monomethyl Ether of Hydroquinone) Guaiacol 4-MAP (4-Methoxy Acetophenone) ➢ Used as polymerization inhibit
Slide 13: Key Differentiators That Add Value
KEY DIFFERENTIATORS THAT ADD VALUE Unique benefits that set our business apart from competition INNOVATION GLOBAL LEADERS PREFERRED PARTNER STATE-OF-THE-ART Strategic process innovation Among the largest OF CHOICE Multiple, automated and new product producers globally of Strong and long term manufac
Slide 14: Steadfast Focus on Research & Development
STEADFAST FOCUS ON RESEARCH & DEVELOPMENT Pioneered commercialization of catalytic reactions Research and Development team’s focus areas Enhance our existing catalyst Develop products with high demand Expand product portfolio in the 1 systems to further optimize yield 2 performance chemical segment
Slide 15: Cohesive and Technocrat Promoters
COHESIVE AND TECHNOCRAT PROMOTERS Strong visibility on longevity of Promoters’ engagement in the business Over 3 decades of work experience in Over 2 decades of experience in the the chemical industry. chemical industry. Bachelor of Chemical Technology – Bachelor of Chemical Engineering – Institute
Slide 16: Robust Corporate Governance
ROBUST CORPORATE GOVERNANCE Distinguished Board of Directors and reputed financial market participants underscore sound governance PROFILE OF NON-EXECUTIVE, INDEPENDENT DIRECTORS ON THE BOARD PRADEEP RATHI PROF. G. D. YADAV Sanjay Kothari Chairman and Non-Executive Director Non-Executive, Independen
Slide 17: Continued Commitment Towards Sustainability and ESG
CONTINUED COMMITMENT TOWARDS SUSTAINABILITY AND ESG Sustainability and ESG initiatives are embedded in our long term growth strategy ENVIRONMENT EMPATHY (E) SOCIAL RESPONSIBILITY (S) CORPORATE GOVERNANCE (G) ➢ Utilize resources efficiently, reduce waste and minimize emissions as part of our ➢ Total
Slide 18: Advanced Manufacturing Facilities Designed by In-House Engineering Team
ADVANCED MANUFACTURING FACILITIES DESIGNED BY IN-HOUSE ENGINEERING TEAM 3 independent functional units under CSTL at Kurkumbh Industrial Area, Maharashtra with dedicated lines for each product UNIT 1 NO plant closure notice received from pollution 7 plants control board Total area – 30,000 sq.m All
Slide 19: Commercialized Largest Facility for HALS from India
COMMERCIALIZED LARGEST FACILITY FOR HALS FROM INDIA Largest facility of Clean Science Group housed in its wholly owned subsidiary, Clean Fino Chem Ltd. at Kurkumbh Industrial Area, Maharashtra UNIT 4 Commercialized in March 2024 Total area – 1,32,700 sq.mtrs. (34 acres) Cost advantage - Tax incentiv
Slide 20: Strong Financial Performance
STRONG FINANCIAL PERFORMANCE Resilient performance demonstrated over business cycles maintaining a debt free balance sheet REVENUE EBITDA & EBITDA% PAT & PAT% CAGR of 16% CAGR of 11% CAGR of 10% 512 685 936 789 922 259 300 403 337 399 198 229 304 248 292 51% 39% 44% 34% 43% 43% 44% 33% 32% 32% FY 20
Slide 21: Our Key Growth Drivers
KEY GROWTH LEVERS Strategic initiatives and investments aimed at long term sustainable growth FOCUS ON ESG AND SIGNIFICANT SUSTAINABILITY GREENFIELD CAPEX Capitalise on our core philosophy Planned capex on track for of clean and green chemistry to commercialising new series of address opportunities
Slide 22: Thank You
THANK YOU For further information, please contact: PRATIK BORA Email: pratik@cleanscience.co.in Clean Science and Technology Limited Website: https://www.cleanscience.co.in/
Clean Science and Technology — Q3 FY2026 Earnings Presentation on 6ix